AMAG AMAG Pharmaceuticals, Inc.

0  -1%
Previous Close 22.80
Open 22.80
Price To book 0.84
Market Cap 774.34M
Shares 34,339,000
Volume 617,118
Short Ratio 7.22
Av. Daily Volume 973,987

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17771542
  2. PRE 14A - Other preliminary proxy statements 17751923
  3. 8-A12B - Registration of securities (Section 12(b)) 17751683
  4. 8-K - Current report 17751657
  5. 8-K - Current report 17743503

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Hypoactive sexual desire disorder (HSDD)
Phase 3 trial to be completed estimated 1H 2017. sNDA due mid 2017.
Adults with iron deficiency anemia (IDA)
sNDA filing announced April 17, 2017. PDUFA date estimated October 17, 2017 assuming 6-month priority review.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET
  2. AMAG Files for FDA Approval of Subcutaneous Form of Makena
  3. AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
  4. AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : April 12, 2017
  5. AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMAG-US : April 11, 2017
  6. 15 companies with outsized sales growth and widening profit margins
  7. AMAG Pharmaceuticals stock surges 4% after closing $50 mln licensing agreement for menopause drug
  8. AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone)
  9. featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
  10. 5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
  11. AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
  12. Billionaires' Worst Healthcare Stock Picks for 2017 (So Far)
  13. AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : March 21, 2017
  14. Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
  15. Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc. (AMAG)
  16. AMAG Announces Management Changes and New Commercial Appointments
  17. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
  18. AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
  19. AMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR
  20. AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017